Assembly Biosciences, Inc. ASMB

Company Overview

Assembly Biosciences, Inc. is a U.S.-based biotechnology company focused on the discovery and development of antiviral therapeutics for serious viral diseases with significant unmet medical need. The company primarily operates within the biopharmaceutical and infectious disease sectors, with a strategic emphasis on chronic hepatitis B virus (HBV), recurrent herpes simplex virus (HSV), and related virology-focused therapeutic areas. Assembly Biosciences generates value primarily through drug discovery, clinical-stage development programs, strategic research collaborations, and licensing arrangements rather than through commercialized product sales.

The company evolved through a combination of biotechnology platform development and strategic restructuring initiatives. Assembly Biosciences was formed through the merger of Assembly Pharmaceuticals and Ventrus Biosciences in 2014, creating a company centered on antiviral drug development. Historically, the company advanced multiple HBV therapeutic candidates, including core inhibitors and entry inhibitors, and later expanded into HSV-focused antiviral programs. A notable strategic relationship with Gilead Sciences has supported portions of its antiviral research activities through collaborative agreements and equity investments. Assembly Biosciences has positioned itself as a specialized antiviral innovator with expertise in small-molecule virology platforms and liver-targeted infectious disease therapeutics.